Skip to Content
Merck
CN

416274

N-Phenylphthalimide

98%

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C14H9NO2
CAS Number:
Molecular Weight:
223.23
UNSPSC Code:
12352100
PubChem Substance ID:
EC Number:
208-282-9
MDL number:
Assay:
98%
Form:
powder
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

MFUPLJQNEXUUDW-UHFFFAOYSA-N

InChI

1S/C14H9NO2/c16-13-11-8-4-5-9-12(11)14(17)15(13)10-6-2-1-3-7-10/h1-9H

SMILES string

O=C1N(c2ccccc2)C(=O)c3ccccc13

assay

98%

form

powder

mp

204-207 °C (lit.)

Storage Class

13 - Non Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

R Shimazawa et al.
Bioorganic & medicinal chemistry letters, 9(4), 559-562 (1999-03-31)
A novel series of nonpeptide small-molecular dipeptidyl peptidase IV (DPP-IV) inhibitors with an N-phenylphthalimide skeleton has been developed. Some of the compounds, including 4-amino-(2,6-dimethylphenyl)phthalimides (7), 4- and 5-hydroxy-(2,6-diethylphenyl)phthalimide (11 and 14), 4-hydroxy-(2,6-diisopropylphenyl)phthalimide (12), and thiocarbonyl analogs of (2,6-diisopropylphenyl)phthalimide and their
Kazunori Motoshima et al.
Biological & pharmaceutical bulletin, 32(9), 1618-1620 (2009-09-02)
Novel glycogen phosphorylase a (GPa) inhibitors with a phenethylphenylphthalimide skeleton were prepared based on alpha-glucosidase inhibitors and liver X receptor (LXR) antagonists derived from thalidomide. Their structure-activity relationships were analyzed. Some of the compounds thus prepared showed potent inhibitory activity
Hiroko Sano et al.
Chemical & pharmaceutical bulletin, 52(8), 1021-1022 (2004-08-12)
Several N-substituted phenylphthalimide and phenylhomophthalimide derivatives with cyclooxygenase (COX)-inhibitory activity were prepared during structural development studies based on thalidomide as a lead compound. Substituent effects on the subtype selectivity were investigated.
The oxidative degradation of imide polymers. I: Ozonolysis of a model compound, N-phenylphthalimide.
Barman S, et al.
Polym. Eng. Sci., 34(4), 279-284 (1994)
Masashi Tetsuhashi et al.
Bioorganic & medicinal chemistry, 18(14), 5323-5338 (2010-06-22)
A novel series of tryptase inhibitors with a N-phenylphthalimide skeleton structurally derived from thalidomide (1) has been developed. Structure-activity relationship studies led to a potent and selective tryptase inhibitor, 2-(4-cyanophenyl)isoindole-1,3-dione-5-yl 3-(2-aminopyridin-5-yl)propanoate (7), with the IC50 value of 78 nM.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service